RxDoctor Payments Data

Domenic Izzo, MD

Ophthalmology · Wyomissing, PANPI 1225028624

Payments from drug & device makers

$1,716in general payments, 2019–2025

Across 73 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$618
  • AbbVie$311
  • Eyevance Pharmaceuticals LLC$132
  • Kala Pharmaceuticals, Inc.$125
  • Johnson & Johnson Surgical Vision, Inc.$116
  • Glaukos Corporation$81
  • plus $335 from 12 others

What the payments were for

  • Consulting fees$664%
  • Food & beverage$1,65096%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,716 in reported general payments places this provider in the 55th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$497,906
Medicare patients
939
Services billed
3,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine59$78,120
Cyclosporine14$13,598
Tobramycin-DexamethasoneTobramycin/Dexamethasone287$9,299
MieboPerfluorohexyloctane/Pf11$8,083
LumiganBimatoprost12$4,069
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol31$3,988
SimbrinzaBrinzolamide/Brimonidine Tart15$3,340
Fluorometholone37$2,878
Latanoprost143$1,127
ErythromycinErythromycin Base69$612
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat23$558
Prednisolone Acetate16$513
Ketorolac Tromethamine30$383
Timolol Maleate15$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$311$82,18871 claims
AlconSimbrinza$618$3,34015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →